We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EWI Edinburgh Worldwide Investment Trust Plc

0.60 (0.41%)
20 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Edinburgh Worldwide Investment Trust Plc LSE:EWI London Ordinary Share GB00BHSRZC82 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.60 0.41% 146.00 145.40 145.80 146.80 143.80 143.80 830,791 16:35:09
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Unit Inv Tr, Closed-end Mgmt -181.6M -182.57M -0.4716 -3.09 563.61M
Edinburgh Worldwide Investment Trust Plc is listed in the Unit Inv Tr, Closed-end Mgmt sector of the London Stock Exchange with ticker EWI. The last closing price for Edinburgh Worldwide Inve... was 145.40p. Over the last year, Edinburgh Worldwide Inve... shares have traded in a share price range of 120.80p to 157.80p.

Edinburgh Worldwide Inve... currently has 387,094,641 shares in issue. The market capitalisation of Edinburgh Worldwide Inve... is £563.61 million. Edinburgh Worldwide Inve... has a price to earnings ratio (PE ratio) of -3.09.

Edinburgh Worldwide Inve... Share Discussion Threads

Showing 51 to 71 of 75 messages
Chat Pages: 3  2  1
Space X launch successful at third attempt !
Edinburgh Worldwide IT

Manager of the Trust, Douglas Brodie hosts

Webinar Tuesday 6th. February at 1400hrs.

Plus Q&A

captain stock
Nevertheless, the portfolio managers, under close scrutiny of the Board, have identified potential improvements to both processes and tactics which should improve the balance of the portfolio. These include being more rigorous in recognising stocks that have had a good run and taking profits where appropriate, and being more ruthless in addressing issues in the tail of the portfolio where the portfolio managers may have tended in the past to err on the side of patience.

Most interesting paragraph from the RNS today - can they please have a better balance of more profitable companies and do not over weight their "long shots" like novocure that can blow up badly. This is very basic stuff and really they should have been doing this all along imvho...

hxxps:// dyor etc

been a long hard bear market since a 4 quid share price - is this a new dawn?

Our confidence in a recovery is underpinned by the absolute valuations of emerging biotech, which are now sitting at unprecedented lows. One objective measure of looking at valuation is to look at the ratio of a company’s market cap to net cash on the company’s balance sheet.

Median ratio for the biotech industry is now at all-time lows, below that of the dot com bust, the Global Financial Crisis, and the Hillary Clinton drug pricing tweet in 2015. About 25% of the biotech universe representing over 120 companies are now trading at market caps below the net cash on their balance sheets.

As we’ve stated before, we have never seen such a large disconnect between biotech company valuations and the fundamental innovation occurring in the industry
(9/11/23 UK biotech trust half year report)

dyor etc

Brodie is BG's new Anderson.

all imo. dyor.

Zillow UP 10% in today's session

Privately owned SpaceX now valued close to $180 billion in new tender offer at $97 per share.

According to trusted Bloomberg today.

A significant uplift in SpaceX valuation which should in due course be reflected in both Scottish Mortgage and even more in Edinburgh Worldwide .

all imo. dyor.

Zillow + 13% in today's USA session
23% discount is going some - highest I think now in its history (certainly last several years) - I wonder if at any point the management are going to do anything about this..
Chart looks horrifying tbh so late into a long decline - prices being paid for some of these holdings seems so high by UK standards (just look at novocure) so I remain unsure what will trigger any change in the downtrend ...imvho dyor etc
Hi Pug, I initially dithered between this and Scottish Mortgage and finally plumped for this after deciding SMT was over valued. My only consolation is although this is down 51% since then so is SMT. I usually top up under performers on the basis that I think my initial assumption was right but not this one. But neither am I selling as I still think one day the market will turn. I guess Polar Capital Technology or Allianz Technology might have been better bets but hindsight is a wonderful thing:-(
This has been an unmitigated disaster for anyone who follows the Daily Mail

First hit my screen144 RE MAIL ARTICLE at 932 15/7/18 re MOS How a mission to discover the world's most exciting companies delivered a 48% gain in just one year

Now being suggested again at 144p - Ouch! Egg all over faces of managers - I know they say Long Term but in the long term we have all passed over or are just dust and bones depending on which fith you follow or do not.

In the COVID tech recovery this shot up and this time around the NASDAQ is well up in 2023 and this part of the market heads ever lower. I looked at some comments today to understand the market conditions better to understand how someone else in this area of the market assessed things. I.e. when we will know there is any sort of recovery to come back in?

BIOG trust update today...

Macroeconomic factors rather than industry fundamentals continued to dominate
portfolio performance during the fiscal year. The fiscal year began with
weakness in the biotech sector in April and May 2022, driven by continued
investor concerns about rising interest rates. Continued rate hikes by the U.S.
Federal Reserve (the Fed) to combat inflation drove down share prices for
unprofitable technology stocks broadly, including emerging biotech. Valuations
for emerging biotech, which had reached 20-year lows, appeared to bottom out in
May and June. In August, drug pricing legislation in the U.S. was passed as part
of the Democrats' "Inflation Reduction Act". While the bill allows for limited
drug price negotiation by Medicare starting in 2026, the provisions appear
manageable for the industry and passage of the bill cleared a longstanding
political overhang for the sector. By the end of September, the biotech sector
had begun staging a recovery from depressed levels. In October, a disappointing
round of earnings from large capitalization (cap) technology stocks like Amazon
and Meta and growing recession concerns appeared to draw generalist inflows into
the defensive pharmaceutical sector and large cap biotech. Large cap biotech
outperformance continued in November, but small cap biotech began outperforming
in December, and January 2023. Unfortunately, interest rate expectations became
more hawkish in February when the U.S. announced a lower-than-expected
unemployment rate and higher-than-expected inflation, sending small cap shares
back down. In March, the unexpected failure of Silicon Valley Bank (SVB) had a
particularly negative impact on small cap biotech, many of which were SVB
clients. Even though absolute cash exposure to SVB for most biotech companies
was minimal, renewed risk aversion due to the concerns over the banking system
caused large cap biotech to significantly outperform small cap biotech. This
trading dynamic had a particularly detrimental impact on the Company's relative
performance versus the Benchmark, given that the Company is significantly
overweight small cap names and underweight large cap names. The drawdown in
March accounted for virtually all of the underperformance of the Company's NAV
versus the Benchmark for the fiscal year. Encouragingly, the Company has seen a
rebound in relative performance in April and May 2023, which we hope signals a
more sustained recovery.
dyor etc

Annual report out today where the company explain their logic for their approach - some very telling comments about their assessment of the current market place for early stage investing in innovative start ups...their take on AI is interesting both for how they see opportunities there...imvho there seems to be differing interpretations of how the AI opportunity is opening up from different investment teams which is what you would expect....
Many years ago, this seemed to have an edge in the market and performed well and now seems other smaller global company trusts have a different composition with different sector emphasis and different relative performances....
One of the top 10 US holdings down 44% yesterday...I have watched this for ages now and it seems to be in a constant down trend not helped by individual stock issues I suspect e.g. Ocado not helping either...dyor etc
Changed days with this one. Historically it trades at around NAV but now on a 19% discount.

Biggest holding is Nasdaq listed Alnylam Pharmaceuticals Inc which is 7.5% of the portfolio followed by Musk's SpaceX at 7%

Yes not looking great here. Another BG Trust. This one is only down 43% year to date although looking at the chart its not that far off its pandemic lows now.
I was just watching the tumble weed blowing along on this board and I came across this on the ewi website. A long and interesting history, with links to James Bond!
I for one will continue to hold on through this particular storm, "if necessary lashed to the wheel".

Chat Pages: 3  2  1

Your Recent History

Delayed Upgrade Clock